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Association between Serum IGF-I 
levels and Postoperative Delirium 
in Elderly Subjects Undergoing 
Elective Knee Arthroplasty
Timothy E. Yen1, John C. Allen1,*, Sarah K. Rivelli2, Stephanie C. Patterson3, 
Meredith R. Metcalf4, Benjamin J. Flink5, Aibek E. Mirrakhimov6, Sandhya A. Lagoo7, 
Thomas P. Vail8, Christopher C. Young9, Richard E. Moon9, Paula T. Trzepacz10,11,* & 
Madan M. Kwatra9,*
Evidence is mixed for an association between serum insulin-like growth factor-I (IGF-I) levels and 
postoperative delirium (POD). The current study assessed preoperative serum IGF-I levels as a predictor 
of incident delirium in non-demented elderly elective knee arthroplasty patients. Preoperative serum 
levels of total IGF-I were measured using a commercially available Human IGF-I ELISA kit. POD 
incidence and severity were determined using DSM-IV criteria and the Delirium Rating Scale-Revised-98 
(DRS-R98), respectively. Median IGF-I levels in delirious (62.6 ng/ml) and non-delirious groups (65.9 ng/
ml) were not significantly different (p = 0.141). The ratio (95% CI) of geometric means, D/ND, was 0.86 
(0.70, 1.06). The Hodges-Lehmann median difference estimate was 7.23 ng/mL with 95% confidence 
interval (−2.32, 19.9). In multivariate logistic regression analysis IGF-I level was not a significant 
predictor of incident POD after correcting for medical comorbidities. IGF-I levels did not correlate with 
DRS-R98 scores for delirium severity. In conclusion, we report no evidence of association between 
serum IGF-I levels and incidence of POD, although the sample size was inadequate for a conclusive 
study. Further efforts to investigate IGF-I as a delirium risk factor in elderly should address comorbidities 
and confounders that influence IGF-I levels.
Delirium is characterized by fluctuating disturbances in attention, memory, orientation, perception, psychomotor 
behavior, and sleep. Postoperative delirium (POD) is a common adverse outcome in patients after major surgery 
with incidence of up to 65%1. Older patients who develop POD are at greater risk for associated short-term and 
long-term negative sequelae. Acutely, POD has been linked to higher rates of inpatient mortality and morbidity, 
in addition to longer hospital stays and higher hospitalization costs2–4. The long-term effects of POD in the elderly 
include neurological impairment5–7, functional decline8, and increased mortality9.
The etiology and pathogenesis of delirium is complex and not well understood. From a clinical standpoint, 
known delirium risk factors include age, previous cognitive impairment, dementia, sleep deprivation, opioid 
pain treatment, exposure to benzodiazepines, and obstructive sleep apnea10,11. On a cellular level, inflammation, 
oxidative stress, apoptosis, and alterations in neurohormonal signaling underlie the clinical manifestations of this 
disorder12. There are ongoing efforts to better understand the molecular basis of delirium in order to gain insight 
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into the direct pathophysiology of the disease and to identify blood predictors to aid in clinical risk determination 
and diagnosis.
Insulin-like growth factor-I (IGF-I) is being investigated as a possible delirium risk predictor. IGF-I is believed 
to be neuroprotective, and low IGF-I levels have been associated with aging and Alzheimer’s dementia, both of 
which are major risk factors for delirium12–15. Thus, it is possible that low levels of IGF-I could predispose to 
the development of POD. However, the evidence remains uncertain. Six research groups have investigated the 
association between circulating IGF-I levels and the onset of delirium in response to surgery or acute medical 
illness16–22. Three authors have found a significant association between low levels of IGF-I and delirium18,19,21,22, 
while three others did not16,17,20. Potential reasons for this discrepancy include small patient cohorts and different 
study designs, IGF-I assay methodology, patient exclusion criteria, patient health status (acutely ill vs healthy), 
and clinical status (postoperative vs medically ill).
In order to better understand the relationship between preoperative serum IGF-I and POD without the con-
found of dementia, we prospectively studied 106 healthy, non-demented elderly subjects undergoing elective 
knee replacement surgery about whom we previously reported a POD incidence of 27%23. We hypothesized 
that subjects with lower levels of plasma IGF-I would be more likely to develop delirium. Indeed, we previously 
presented a preliminary analysis of 85 subjects from this cohort that found a statistically significant association 
between lower preoperative plasma IGF-I levels and increased incidence and severity of POD24. We now report 
our final analysis (n = 98).
Results
Baseline Comparisons. Table 1 shows clinical characteristics at baseline comparing delirious (D) (n = 22) 
and non-delirious (ND) (n = 76) groups. There were no significant differences between D and ND groups for 
demographic characteristics, preoperative hemoglobin, oxygen saturation, or medical comorbidities except for 
obstructive sleep apnea, which was more common in the D group (ND, 9.2%; D, 31.8%; p = 0.014).
The distributions of IGF-I levels for the D and ND groups exhibited considerable overlap (Fig. 1). Mean (SD) 
preoperative serum IGF-I levels (ng/mL) were 57.0 (18.6) in the D group and 68.4 (31.6) in the ND group. Study 
groups were compared using a 2-sample t-test after taking logarithms, resulting in a non-significant difference 
(p = 0.146). Geometric means (GSD) were ND: 62.3 (1.10) and D: 53.6 (1.07). GSDs were sufficiently similar to 
warrant a pooled estimate in calculating a confidence interval on the GM ratio. The GM ratio and 95% CI for 
D/ND was 0.86 and (0.70, 1.06) indicating that mean preoperative IGF-I level in delirium subjects was 14% lower 
Variable
Non-Delirious 
(n = 76) Delirious (n = 22) P-value1
Demographic and Clinical Characteristics
Age (years) 73.7 ± 5.2 72.5 ± 4.4 0.351
Sex (female) 50% 59% 0.479
Caucasian 92.1% 81.8% 0.225
BMI 31.1 ± 7.3 31.7 ± 7.6 0.692a
Education (years) 14.9 ± 3.2 14.6 ± 3.2 0.663
ASA score of 3† 60.5% 54.6% 0.631
Mini-Mental State Exam, median (range) 30 (24, 30) 29 (26, 30) 0.161b
Hemoglobin (g/dl) 13.4 ± 1.6 13.3 ± 1.1 0.718
Preoperative % oxygen saturation 96.9 ± 1.6% 97 ± 1.7% 0.800
Number of preoperative comorbidities 3.4 ± 1.8 3.2 ± 1.4 0.711
Frequency of comorbidities:
 Coronary artery disease 15.8% 27.3% 0.226
 Diabetes 10.5% 22.7% 0.159
 Hypertension 75.0% 81.8% 0.582
 Hyperlipidemia 44.7% 45.5% 1.000
 Obstructive sleep apnea 9.2% 31.8% 0.014
 Benign prostatic hypertrophy 19.7% 9.1% 0.345
 Incontinence 11.8% 9.1% 1.000
 Gastroesophageal reflux disorder 32.9% 31.8% 1.000
Preoperative IGF-I serum level (ng/mL)
 Mean ± SD 68.4 ± 31.6 57.0 ± 18.6 –a
 Geometric mean (Geom. SD) 62.3 (1.10) 53.6 (1.07) 0.146b
 Median (range) 65.9 (17.2, 204) 62.6 (19.6, 87.3) 0.141c
Table 1.  Baseline (preoperative) demographic variables, subject characteristics and IGF-I levels. †All 
subjects had a preoperative ASA score of either 2 (mild systemic disease) or 3 (severe systemic disease). 
1Two-sample t-test (equal or unequal variances as appropriate) on continuous variables for which normality 
assumption is tenable, unless indicated otherwise; Fisher’s exact on categorical variables. aTwo-sample t-test 
p = 0.037, but outliers make normality assumption untenable. bTwo-sample t-test on logarithms. cTwo-sample 
(rank-sum) Wilcoxon test.
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than in non-delirium subjects and could be as much as 30% lower or 6% higher. Study group medians were ND: 
65.9 and D: 62.6 ng/mL which were not significantly different by the Wilcoxon rank-sum test (p = 0.141). The 
Hodges-Lehmann median difference estimate was 7.23 ng/mL with 95% confidence interval (− 2.32, 19.9).
POD Prediction Analyses. Nineteen clinical baseline variables (Table 1) were assessed as potential pre-
dictors of POD using univariate logistic regression. Variables significant at p ≤ 0.15 were obstructive sleep apnea 
(p = 0.012), IGF-I concentration (p = 0.108), and diabetes (p = 0.147).
Multivariate regression analysis also resulted in IGF-I as a non-significant risk factor for POD (OR = 0.985, 
95% CI: 0.964, 1.007; p = 0.183) after adjustment for obstructive sleep apnea (p = 0.024) and diabetes (p = 0.273) 
(Table 2).
Presence of obstructive sleep apnea increased the odds of developing POD by a factor of 4.60 (95% CI 1.40–
15.1; p = 0.012) in the univariate logistic regression analysis and by 4.06 (95% CI; 1.21–13.7; p = 0.024) after 
adjustment for IGF-I and diabetes. Univariate area under the curve (AUC) (95% CI) for obstructive sleep apnea 
was 0.61 (0.51, 0.72). As previously reported, obstructive sleep apnea remained the only significant, independent 
predictor of POD in the multivariate analyses23.
Delirium Severity. As expected, mean DRS-R98 scores were significantly different for delirious and 
non-delirious groups for Total (D: 16.1 ± 5.73, ND: 3.70 ± 3.62; p < 0.0001) and Severity scale scores (D: 
10.7 ± 4.98, ND: 2.07 ± 2.05; p < 0.0001). No preoperative clinical variable studied in the univariate or multivar-
iate regression analysis was significantly associated with delirium severity.
Discussion
We report our final study results on the evaluation of serum IGF-I as a potential predictor of risk of post-operative 
incident delirium in 98 healthy, non-demented elderly patients who underwent elective knee surgery. Our study 
team previously presented interim results from this cohort that found a significant association between lower 
preoperative plasma IGF-I levels and both increased incidence (p = 0.012) and severity (p = 0.018) of POD24. 
However, we did not find a significant relationship in this final report. One notable difference between our 
Figure 1. Distributions of preoperative IGF-I serum levels by percentage for delirious and non-delirious 
groups. The distributions of IGF-I concentrations for the Delirious and Non-delirious groups exhibited 
considerable overlap, and there was no difference in median IGF-I levels between groups.
Variable
Univariate1 Multivariate
Odds ratio with 
Confidence Interval P-value
Odds ratio with 
Confidence Interval P-value
Obstructive sleep apnea 4.60 (1.40, 15.1) 0.012 4.06 (1.21, 13.7) 0.024
Diabetes 2.50 (0.73, 8.62) 0.147 2.08 (0.56, 7.66) 0.273
IGF-I Level 0.983 (0.962, 1.004) 0.108 0.985 (0.964, 1.007) 0.183
Table 2. Results of Univariate and Multivariate Analysis. Results of the univariate logistic regression analyses 
investigating 19 variables as potential predictors of post-operative delirium incidence and of the multivariate 
analysis using the 3 variables significant at p ≤ 0.15 in the univariate analysis. Significant results are bolded. 
1Age, sex, race, ASA score, MMSE score, education, BMI, preoperative hemoglobin and oxygen saturation, 
number of preoperative comorbidities, CAD, hypertension, hyperlipidemia, BPH, incontinence and GERD had 
p-values > 0.15 in univariate analysis and were not included in the multivariate analysis. Only OSA, Diabetes 
and IGF-I levels were included in the multivariate analysis.
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previous, unpublished abstract and this current report is that we measured serum IGF-I levels instead of plasma 
IGF-I levels because patient serum samples had been collected for a larger number of subjects. Measurement of 
IGF-I in plasma and serum is similar but not identical. Serum has been shown to have a higher overall concen-
tration of metabolites than plasma, and certain analytes are easier to detect in serum25,26. With respect to IGF-I, 
serum has been shown to yield 5–10% higher IGF-I levels than plasma when measured27.
Since there are currently no reliable molecular predictors for POD, we were interested in assessing the util-
ity of IGF-I as a potential candidate. We studied a relatively healthy and well-educated (D 14.9 ± 3.2 years, ND 
14.6 ± 3.2 years) population of non-demented, elderly subjects so we could understand the relationship of this 
protein with delirium without the confounding effect of preexisting cognitive impairment. In fact, our careful 
exclusion of dementia and cognitive complaints along with its high education level suggest our population had 
high cognitive reserve, which is known to be an important protective factor for dementia28. Individuals with high 
cognitive reserve can accumulate the underlying pathophysiology of dementia without overt cognitive symptoms 
of dementia or delirium28. This suggests that some individuals with low IGF-I levels in our study might have been 
able to tolerate an underlying pathophysiological change without developing delirium. The high cognitive reserve 
of our sample may also make it unrepresentative of the general community population. Taken together with prior 
literature, our findings suggest that low IGF-I might instead be a biomarker for some other underlying neuro-
physiological condition that is actually the delirium risk factor, such as a neurodegenerative process.
There was considerable overlap in the distributions of serum IGF-I levels between groups. Some individuals 
with higher IGF-I levels developed delirium whereas many individuals with lower IGF-I levels did not. This was 
reflected by the failure of IGF-I concentration to achieve statistical significance as a predictor of POD. Our sam-
ple size was comparable with the largest published studies; however, the 95% confidence interval on the IGF-I 
adjusted odds ratio did not exclude unity. As such, our sample size was inadequate for a conclusive study. The 
question of statistical power and whether the sample size was adequate hinges on the clinical issue of whether 
the 95% confidence interval excludes a clinically relevant difference—what is the largest difference that would be 
considered clinically irrelevant, is it 30% or is it less than 30%? ROC analysis (not shown) found that overall total 
IGF-I levels, based on our assay, are a poor predictor of POD, and that sensitivity + specificity was maximized 
at IGF-I = 85 ng/ml corresponding to sensitivity = 0.90, specificity = 0.25, NPV = 0.90 and PPV = 0.30 for POD 
(using the observed 27% prevalence in this study).
Furthermore, our data do not support any association between total IGF-I levels and severity of delirium as 
measured by the DRS-R98. And the DRS-R98 is a more sophisticated measure of delirium phenomenology than 
the simpler diagnostic approaches of incidence that prior reports have used.
It is also possible that total IGF-I concentration is only weakly associated with POD, that confounders mask 
the effect of total IGF-I, or that delirium associated with acute medical illness is more linked to an IGF-I relation-
ship than is the brief biological stressor of elective orthopedic surgery. A weak association as well as generally 
inadequate sample sizes could explain why previous studies have not consistently found a statistically significant 
association between IGF-I levels and risk of POD. Compared with five studies that have looked at delirium in 
acutely ill medical patients, only two studies, Lemstra et al. and Cerejeira et al., have investigated IGF-I levels in 
POD and neither has found an association17,20. Of these two, only Cerejeira et al. excluded patients with baseline 
dementia or cognitive dysfunction.
The role of IGF-I binding proteins (IGFBP) in POD is both important and understudied. IGF-I exists in circu-
lation bound to one of six different IGFBPs29,30. The assay in our study measured total IGF-I (bound + unbound) 
rather than a specific fraction. No previous report has examined the relationship of a specific fraction of IGF-I to 
POD16–22. Measuring total IGF-I levels offers only a limited picture, as differences in IGFBP profile can produce 
changes in the biologically active, unbound free-fraction of IGF-I31. Diseases like renal failure and diabetes can 
cause an increase in circulating IGFBPs, while certain conditions that lower IGFBP-I and -II can increase the 
free IGF-I levels32,33. Additionally, serum IGFBPs degrade easily, and excessive freeze/thaw cycles or suboptimal 
storage conditions can introduce error into an analysis34. Studies tailored to measure free IGF-I or IGFBPs may 
provide a clearer picture of IGF-I’s true influence.
In addition, numerous variables including circadian rhythm, nutritional state, renal function and hormone 
and insulin levels have been shown to affect IGF-I expression35–40. These variables were not addressed in our 
study, and therefore may confound our results.
An ideal predictor should be both a sensitive and specific detector of a disease state41. Unfortunately, preop-
erative total IGF-I levels in our study fail to reliably rule-in or rule-out the development of POD at IGF-I cutoffs 
outside of either the high or low extremes. Further, assay standardization and validity for determining abnormal 
cutoff values would need to be developed across a large and diverse community sample population. Alternatively, 
a meta-analysis could be used to answer the question IGF-I’s prognostic value in POD. However, at present there 
are not enough suitable candidate studies to pool, as only our study and Cerejeira et al. focus on healthy patients 
in an elective surgical setting. If in the future other research groups use compatible study designs to publish on 
this research question, then a meta-analysis could become a viable tool.
In conclusion, our study failed to show a statistically significant difference in mean IGF-I total serum levels 
between post-operative delirious and non-delirious subjects, and evidence for IGF-I as a predictor for POD was 
not found. There are currently no studies supporting a clear association between total IGF-I serum levels and 
POD. We recommend that future work evaluating a relationship between circulating IGF-I and POD investigate 
free IGF-I while controlling for potential confounders.
Materials and Methods
Subjects and Clinical Procedures. This prospective study enrolled 106 elderly subjects undergoing elec-
tive knee replacement surgery. Subjects were evaluated for delirium prior to surgery and on postoperative days 2 
and 3. Subjects were recruited from Duke University Medical Center and the Durham Veterans Affairs Medical 
www.nature.com/scientificreports/
5Scientific RepoRts | 6:20736 | DOI: 10.1038/srep20736
Center. Inclusion criteria included age ≥ 65 years, prior scheduling for elective knee replacement, and written 
informed consent per the Duke University Health System IRB (DUHS IRB). Subjects were excluded from the 
study if they had 1) ongoing major depression 2) psychosis or active alcohol or substance abuse within the last 
three months 3) preexisting delirium, dementia or cognitive impairment defined as an MMSE score less than 24 
or 4) any clinically significant neurologic disorder. The experimental protocol was approved by DUHS IRB and 
was carried out in accordance with its guidelines.
Preoperative cognitive function was assessed using the Mini-Mental State Examination (MMSE)42, a chart 
review for prior diagnoses of dementia, and a semi-structured interview with the subject and family mem-
ber. Subjects were assessed by trained research team members for preoperative delirium using the four-item 
Confusion Assessment Method (CAM)43 and the 16-item Delirium Rating Scale-Revised-98 (DRS-R98)44. The 
DRS-R98 is a well-validated tool that can be used to both diagnose delirium (using the 46-point Total scale) and 
measure the severity of delirium (using the 39-point Severity scale)45.
Subjects were then evaluated for delirium and delirium severity again following surgery on postoperative 
days 2 and 3 using the CAM and DRS-R98, respectively. Delirium was diagnosed by the study psychiatrist in 
accordance with the criteria described in the Diagnostic and Statistical Manual for Psychological Disorders, 4th 
edition (DSM-IV) based on an in-person assessment and a review of the daily CAM, DRS-R98 and medical 
records. Additionally, subject American Society of Anesthesiologists Physical Status Classification (ASA) scores 
were obtained from anesthesiology charts. ASA scores estimate preoperative physical health on a six- (previously 
four-) point scale based on the presence and severity of systemic disease46,47.
Laboratory Methods. Of the original 106 subjects enrolled in this study, serum was available from 98 indi-
viduals. After each assessment (baseline, post-op day 1 and post-op day 2) 15–20 mL of blood was collected from 
each patient (Three EDTA-containing tubes for plasma and peripheral blood mononuclear cell isolation and one 
plain tube for serum isolation). These products were flash frozen in liquid nitrogen and stored in a − 80 °C freezer 
until use.
Preoperative IGF-I total serum levels were measured using Human IGF-I Quantikine ELISA kits (R&D 
Systems, Minneapolis, USA) and values expressed as concentrations (ng/ml). The ELISA was conducted accord-
ing to the manufacturer’s instructions, and the subject samples were assayed in duplicate and values averaged. All 
duplicates possessed < 10% coefficient of variation.
Statistical Analysis. Data were analyzed using the SAS version 9.3 (SAS Inc., Cary, NC USA) statistical 
package. Categorical variables were summarized as frequencies and percentages, and Fisher’s exact test was used 
to compare study groups on categorical variables. Normally distributed baseline variables were summarized as 
mean ± SD and D and ND groups compared using a 2-sided, 2-sample t-test taking into account equal or unequal 
variances. The distribution of baseline IGF-I concentrations among non-delirious subjects was right-skewed with 
extreme values rendering the normality assumption untenable. However, taking logarithms sufficiently normal-
ized the non-delirious distribution and retained approximate normality in the delirious group to enable a com-
parison using a 2-sample t-test. Consistent with the logarithmic analysis, geometric means (GM) and standard 
deviations (GSD) were reported as sample statistics—note that GM × GSD approximates the arithmetic mean. 
A 95% confidence interval on the GM ratio of baseline IGF-I concentrations was obtained from the logarithmic 
analysis. In addition, we obtained the non-parametric Hodges-Lehmann median difference estimate and a 95% 
distribution free (Moses) confidence interval.
POD was defined as presence of delirium on postoperative day 2 and/or 3. POD was analyzed as a binary out-
come (present/absent) and as a measurable variable based on the DRS-R98 POD severity scale. Univariate logistic 
regression analysis was used to evaluate pre-operative subject characteristics as predictors of POD (presence/
absence). Variables in the univariate analysis with p ≤ 0.15 were entered into a multivariate analysis. In the subset 
of subjects with POD, association of DRS-R98 Total score and Severity score with baseline variables was assessed 
using univariate least squares regression for continuous baseline variables and a 2-sample t-test for categorical 
variables. Baseline variables significant at p ≤ 0.15 were entered into a multivariate analysis (not shown).
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